BioSpace News Archive

Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, announced the appointment of Lori Kunkel, MD, to its Board of Directors.

Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”) is pleased to announce that members of the Company’s scientific team presented new data on the Company’s novel kt-3000 series at the American Association of Cancer Research (AACR) Annual Meeting at the San Diego Convention Center.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2024 results after the financial markets close on Thursday, May 2, 2024.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced the presentation of interim efficacy and safety data from the Phase 2 TATCIST open-label clinical trial evaluating FPI-2265, at the American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10 in San Diego, California.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close.

Foghorn® Therapeutics Inc. announced new preclinical data for potential first-in-class medicines including FHD-909, a BRM selective inhibitor, selective CBP degrader, and selective EP300 degrader programs at the 2024 American Association for Cancer Research Annual Meeting.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, April 30th, 2024.

DENTSPLY SIRONA Inc. announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 2, 2024, at 8:30 am ET to review its first quarter financial results.

Xencor, Inc. today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer.

In a significant stride towards transforming cardiovascular healthcare in concierge specialty and primary care offices, Exponential Health, an innovative concierge medical practice led by Dr. William Baer, is set to offer Cardio Diagnostics Holdings, Inc.’s clinical epigenetic-genetic cardiovascular tests, Epi+Gen CHD and PrecisionCHD, to their patients.